Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study

Drug Safety

Volumn 40, Issue 9, 2017, Pages 835-840

  Quinn, Kieran L ^a,g   Macdonald, Erin M ^b   Gomes, Tara ^b,c,d   Mamdani, Muhammad M ^b,c,d,e,f   Huang, Anjie ^b   Juurlink, David N ^b,c,d,g  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

^f Canada   (Canada)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFUROXIME; CLARITHROMYCIN; DIGOXIN; ERYTHROMYCIN; ANTIINFECTIVE AGENT; CARDIOTONIC AGENT; MACROLIDE;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; DIGITALIS INTOXICATION; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SUDDEN DEATH; VERY ELDERLY; ATRIAL FIBRILLATION; COMPARATIVE STUDY; DRUG INTERACTION; EPIDEMIOLOGY; HEART FAILURE; ONTARIO; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ATRIAL FIBRILLATION; AZITHROMYCIN; CARDIOTONIC AGENTS; CASE-CONTROL STUDIES; CEFUROXIME; CLARITHROMYCIN; DEATH, SUDDEN; DIGOXIN; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; HEART FAILURE; HUMANS; MACROLIDES; MALE; ONTARIO; RISK FACTORS;

EID: 85017607334     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-017-0539-9     Document Type: Article

References (32)

1. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, et al. focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30:1114–30.
2. McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, et al. The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines update: focus on acute and chronic heart failure. Can J Cardiol (Elsevier Inc). 2013;29(2):168–81.
3. Fishkind D, Paris BE, Aronow WS. Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1997;45(7):809–12.
4. Cheng JWM, Rybak I. Use of digoxin for heart failure and atrial fibrillation in elderly patients. Am J Geriatr Pharmacother. 2010;8(5):419–27.
5. Adams KF, Ghali JK, Herbert Patterson J, Stough WG, Butler J, Bauman JL, et al. A perspective on re-evaluating digoxin’s role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile. Eur J Heart Fail. 2014;16(5):483–93.
6. Mooradian AD. Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clin Pharmacokinet. 1988;15(3):165–79.
7. Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660–8.
8. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, et al. Increased mortality among patients taking digoxin–analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481–8.
9. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.
10. Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN, et al. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). Congest Heart Fail. 2010;16(5):191–5.
11. Teodorescu C, Reinier K, Uy-Evanado A, Gunson K, Jui J, Chugh SS. Resting heart rate and risk of sudden cardiac death in the general population: influence of left ventricular systolic dysfunction and heart rate-modulating drugs. Heart Rhythm. 2013;10(8):1153–8.
12. Digitalis Investigation Group, Ahmed A, Waagstein F, Pitt B, White M, Zannad F, et al. Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol. 2009;103(1):82–7.
13. Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J, et al. Role of P-glycoprotein inhibition for drug interactions. Clin Pharmacokinet (Springer International Publishing). 2007;46(12):1039–49.
14. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther. 1998;64(1):123–8.
15. Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci. 2010;113(4):315–24.
16. Rengelshausen J, Göggelmann C, Burhenne J, Riedel K-D, Ludwig J, Weiss J, et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction. Br J Clin Pharmacol. 2003;56(1):32–8.
17. Tanaka H, Matsumoto K, Ueno K, Kodama M, Yoneda K, Katayama Y, et al. Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother. 2003;37(2):178–81.
18. Zapater P, Reus S, Tello A, Torrús D, Pérez-Mateo M, Horga JF. A prospective study of the clarithromycin-digoxin interaction in elderly patients. J Antimicrob Chemother. 2002;50(4):601–6.
19. Gomes T, Mamdani MM, Juurlink DN. Macrolide-induced digoxin toxicity: a population-based study. Clin Pharmacol Ther. 2009;86(4):383–6.
20. Ouyang A-J, Lv Y-N, Zhong H-L, Wen J-H, Wei X-H, Peng H-W, et al. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol. 2015;115(7):901–6.
21. Pastori D, Farcomeni A, Bucci T, Cangemi R, Ciacci P, Vicario T, et al. Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. Int J Cardiol. 2015;1(180):1–5.
22. Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015;385(9985):2363–70.
23. Chou H-W, Wang J-L, Chang C-H, Lai C-L, Lai M-S, Chan KA. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis. 2015;60(4):566–77.
24. Rao GA, Mann JR, Shoaibi A, Bennett CL, Nahhas G, Sutton SS, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med. 2014;12(2):121–7.
25. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881–90.
26. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351(11):1089–96.
27. Straus SMJM, Sturkenboom MCJM, Bleumink GS, Dieleman JP, van der Lei J, de Graeff PA, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26(19):2007–12.
28. Zambon A, Polo Friz H, Contiero P, Corrao G. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case–control, case–crossover and case–time–control designs. Drug Saf. 2009;32(2):159–67.
29. Schultz SE, Rothwell DM, Chen Z, Tu K. Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can. 2013;33(3):160–6.
30. Fralick M, Macdonald EM, Gomes T, Antoniou T, Hollands S, Mamdani MM, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ. 2014;349:g6196.
31. Chung CP, Murray KT, Stein CM, Hall K, Ray WA. A computer case definition for sudden cardiac death. Pharmacoepidemiol Drug Saf. 2009;19(6):563–72.
32. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013;368(18):1704–12.